IRLAB Therapeutics AB (publ)
STO: IRLAB-A.ST0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Stockholm Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Kristina Torfgard
- Employees
- 31
- Headquarters
- Gothenburg, Sweden
- IPO year
- 2017
- Market cap
- SEK 106.8M
- Website
- https://www.irlab.se
Loading IRLAB-A…
Loading profile data…Frequently asked questions about IRLAB-A
What does IRLAB Therapeutics AB (publ) (IRLAB-A.ST) do?
IRLAB Therapeutics AB (publ) develops drugs for the treatment of Parkinson's disease. The company develops Mesdopetam that is in phase IIb/III clinical studies for the treatment of dyskinesia; and Pirepemat, which is in phase IIb clinical trial for the treatment of Postural dysfunction. Its preclinical stage products include IRL942 and 1009 rese...
Where does IRLAB-A.ST trade?
IRLAB Therapeutics AB (publ) (IRLAB-A.ST) trades on the Stockholm Stock Exchange.
What sector is IRLAB-A.ST in?
IRLAB Therapeutics AB (publ) (IRLAB-A.ST) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of IRLAB Therapeutics AB (publ)?
Kristina Torfgard is the chief executive officer of IRLAB Therapeutics AB (publ) (IRLAB-A.ST).
Where is IRLAB Therapeutics AB (publ) headquartered?
IRLAB Therapeutics AB (publ) is headquartered in Sweden.
Does IRLAB-A.ST pay a dividend?
IRLAB Therapeutics AB (publ) (IRLAB-A.ST) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did IRLAB-A.ST go public?
IRLAB Therapeutics AB (publ) (IRLAB-A.ST) completed its initial public offering in 2017.